Drug Trial Radar · NCT00121407
Visudyne® in Occult (VIO)
Last checked: Nov 20, 2026Latest source record: Jul 21, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
364
Actual
Start
Mar 2002
Primary completion
Not stated
Study completion Aug 2005
Sponsor
- Lead sponsor
- QLT Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable safety profile, significantly reduce the risk of vision loss compared with placebo (sham treatment).
Conditions
- Macular Degeneration
Interventions
Visudyne for injectionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy variable is the patient responder rate. The patient responder rate has two definitions as described below:
- • The proportion of patients who lose less than 15 letters (<3 lines) of best-corrected visual acuity in the study eye from baseline
- • The proportion of patients who lose fewer than 30 letters (<6 lines) of best-corrected visual acuity in the study eye from baseline
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.